Clinical Trial

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
Protocol Amendment History 4 changes
notable Trial sites expanded: 22 -> 47 locations 2026-05-13
notable Trial sites reduced: 44 -> 22 locations 2026-05-06
notable Trial sites expanded: 39 -> 43 locations 2026-04-15
notable Trial sites expanded: 36 -> 39 locations 2026-04-02
Trial Details
NCT Number NCT07073820
Lead Sponsor Pfizer
Conditions Pulmonary Hypertension
Enrollment 36 participants
Start Date 2025-11-10
Primary Completion 2028-07-18 (estimated)
Study Completion 2028-07-18 (estimated)
Updated on ClinicalTrials.gov 2026-05-19